Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of tolperisone (a non-opioid) or placebo administered as multiple doses three times a day (TID) in approximately 400 male and female subjects experiencing back pain due to or associated with muscle spasm.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tolperisone 50 mg | Experimental | TID (150 mg/day) |
|
| Tolperisone 100 mg | Experimental | TID (300 mg/day) |
|
| Tolperisone 150 mg | Experimental | TID (450 mg/day) |
|
| Tolperisone 200 mg | Experimental | TID (600 mg/day) |
|
| Placebo | Placebo Comparator | TID |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tolperisone | Drug | TID |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Effect Size in Subjected-Rated Pain | Mean effect size between Tolperisone and Placebo of subject-rated pain due to acute back spasm using a Numerical Rating Scale (NRS; 0-10 scale, from no pain to worst possible pain) on Day 14 "right now." | Day 1 to Day 14 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tennessee Valley Pain Consultants | Huntsville | Alabama | 35801 | United States | ||
| Fiel Family and Sports Medicine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Tolperisone 50 mg | TID (150 mg/day) Tolperisone: TID |
| FG001 | Tolperisone 100 mg | TID (300 mg/day) Tolperisone: TID |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 2, 2019 | Oct 19, 2020 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo |
|
| Tempe |
| Arizona |
| 85283 |
| United States |
| Center of Applied Research | Little Rock | Arkansas | 72212 | United States |
| Research Center of Fresno | Fresno | California | 93702 | United States |
| Long Beach Clinical Trials Services, Inc. | Long Beach | California | 90806 | United States |
| Northern California Research | Sacramento | California | 95628 | United States |
| Pacific Research Network, LLC | San Diego | California | 92103 | United States |
| San Diego Sports Medicine | San Diego | California | 92120 | United States |
| CITrials | Santa Ana | California | 92705 | United States |
| Riverside Clinical Research | Edgewater | Florida | 32132 | United States |
| Empirical Research Group | Gainesville | Florida | 32653 | United States |
| LLC Medical Research | Miami | Florida | 33126 | United States |
| Savin Medical Group | Miami Lakes | Florida | 33014 | United States |
| Avail Clinical Research | Orange City | Florida | 32763 | United States |
| Private Practice | Plantation | Florida | 33313 | United States |
| NeuroTrials Research, Inc. | Atlanta | Georgia | 30342 | United States |
| Georgia Institute for Clinical Research | Marietta | Georgia | 30060 | United States |
| Georgia Clinical Research | Snellville | Georgia | 30078 | United States |
| MediSphere Medical Research Center | Evansville | Indiana | 47714 | United States |
| Otrimed Clinical Research | Edgewood | Kentucky | 41017 | United States |
| Centex Studies, Inc. | Lake Charles | Louisiana | 70601 | United States |
| Center for Rheumatology and Bone | Wheaton | Maryland | 20902 | United States |
| Michigan Head Pain and Neurological | Ann Arbor | Michigan | 48104 | United States |
| Sundance Clinical Research | St Louis | Missouri | 63141 | United States |
| Jubilee Clinical Research | Las Vegas | Nevada | 89106 | United States |
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | 87102 | United States |
| Upstate Clinical Research Associates | Williamsville | New York | 14221 | United States |
| Clinical Trials of America | Winston-Salem | North Carolina | 27103 | United States |
| Sterling Research Group- Springdale | Cincinnati | Ohio | 45246 | United States |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
| Center for Providence Health Partners | Dayton | Ohio | 45439 | United States |
| IPS Research | Oklahoma City | Oklahoma | 73103 | United States |
| Williamette Valley Clinical Studies | Eugene | Oregon | 97404 | United States |
| Frontier Clinical Research, Inc. | Smithfield | Pennsylvania | 15478 | United States |
| Omega Medical Research | Warwick | Rhode Island | 02886 | United States |
| Health Concepts | Rapid City | South Dakota | 57702 | United States |
| Inquest Clinical Research | Baytown | Texas | 77521 | United States |
| DiscoveResearch, Inc. | Bryan | Texas | 77802 | United States |
| HD Research Corp | Houston | Texas | 77004 | United States |
| Centex Studies, Inc. | McAllen | Texas | 78504 | United States |
| ClinRX Research Joseph, Inc. | Plano | Texas | 75007 | United States |
| Highland Clinical Research | Salt Lake City | Utah | 84124 | United States |
| Health Research of Hampton Roads, Inc. | Newport News | Virginia | 23606 | United States |
| FG002 | Tolperisone 150 mg | TID (450 mg/day) Tolperisone: TID |
| FG003 | Tolperisone 200 mg | TID (600 mg/day) Tolperisone: TID |
| FG004 | Placebo | TID Placebo: Placebo |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Tolperisone 50 mg | TID (150 mg/day) Tolperisone: TID |
| BG001 | Tolperisone 100 mg | TID (300 mg/day) Tolperisone: TID |
| BG002 | Tolperisone 150 mg | TID (450 mg/day) Tolperisone: TID |
| BG003 | Tolperisone 200 mg | TID (600 mg/day) Tolperisone: TID |
| BG004 | Placebo | TID Placebo: Placebo |
| BG005 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Mean | Full Range | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Body Mass Index | Mean | Full Range | kilogram/meter^2 |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Effect Size in Subjected-Rated Pain | Mean effect size between Tolperisone and Placebo of subject-rated pain due to acute back spasm using a Numerical Rating Scale (NRS; 0-10 scale, from no pain to worst possible pain) on Day 14 "right now." | Posted | Mean | 95% Confidence Interval | score on a scale | Day 1 to Day 14 |
|
|
|
First Dose, Day 1 to Follow-up, Day 28
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Tolperisone 50 mg | TID (150 mg/day) Tolperisone: TID | 0 | 82 | 0 | 82 | 7 | 82 |
| EG001 | Tolperisone 100 mg | TID (300 mg/day) Tolperisone: TID | 0 | 87 | 0 | 87 | 13 | 87 |
| EG002 | Tolperisone 150 mg | TID (450 mg/day) Tolperisone: TID | 0 | 83 | 0 | 83 | 12 | 83 |
| EG003 | Tolperisone 200 mg | TID (600 mg/day) Tolperisone: TID | 0 | 85 | 0 | 85 | 14 | 85 |
| EG004 | Placebo | TID Placebo: Placebo | 0 | 78 | 0 | 78 | 5 | 78 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | Systematic Assessment |
| ||
| Dizziness | Nervous system disorders | Systematic Assessment |
| ||
| Somnolence | Nervous system disorders | Systematic Assessment |
| ||
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Randall Kaye, MD - Chief Medical Officer | Neurana Pharmaceuticals, Inc. | 858-732-0708 | rkaye@neuranapharma.com |
| Prot_001.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Aug 6, 2019 | Oct 19, 2020 | SAP_000.pdf |
| ID | Term |
|---|---|
| D001416 | Back Pain |
| D059787 | Acute Pain |
| D009120 | Muscle Cramp |
| D013035 | Spasm |
| D017116 | Low Back Pain |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D020879 | Neuromuscular Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014049 | Tolperisone |
| ID | Term |
|---|---|
| D011427 | Propiophenones |
| D007659 | Ketones |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|